The Clinical Institute of Hematology and Oncology is a national and international reference point for the care of people with malignant blood diseases and solid tumors at different stages of their process. A comprehensive ongoing review is carried out of the patient in the diagnosis and treatment phases, as well as in apheresis (procedure for obtaining stem cells and hematopoietic progenitors) and in the administration of cell therapies. This comprehensive ongoing review is also carried out for patients with alterations in blood clotting (hemostasis).
ICMHO works to provide safe, quality patient care, based on scientific evidence, while taking into account the complexity of each case and making the most of innovation. At the same time, the ICMHO is working on the prevention, early detection and treatment of cancer in the Barcelona Esquerra area and the C-17 area. It is also, for all of Catalonia, a reference point for both various malignant diseases, and highly complex therapeutic procedures.
All healthcare practice is spelled out in clinical guidelines that have been agreed upon with the rest of the hospital services involved in the clinical committees responsible for the diagnosis and treatment of hematological and oncological diseases.
The ICHMO provides patients with the most effective known treatments, conventional or experimental, in the framework of clinical trials, and also guarantees a multidisciplinary approach to treating all aspects of the disease.
The Institute also trains students and healthcare professionals both inside and outside the hospital and disseminates clinical and scientific knowledge, as well as fundamental values, such as respecting the patient.
At the same time, the ICHMO is leading the way in cancer research with the ongoing evaluation of patients, with its participation in translational clinical trials with new targeted treatments or in basic research applied to daily care.